Clearmind Urges FDA to Consider At-Home Pathways for Non-Hallucinogenic Psychedelic Therapies

Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens, announced on October 7, 2026 that it submitted recommendations to the U.S. Food and Drug Administration (FDA). The submission responds to the agency’s public hearing and request for comments on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs,” and focuses on patient access for treatments like the one Clearmind is developing for alcohol use disorder (AUD).

What Clearmind Asked the FDA to Consider

Under FDA Docket No. FDA-2026-N-7542, Clearmind recommended that the agency consider new guidance for self-administered and at-home-potential therapies. It also called for streamlined regulatory pathways, expanded clinical trial access and greater use of Breakthrough Designation to help bring new therapies to market.

In addition, the company proposed research and clinical collaborations with the U.S. Department of Veterans Affairs, the U.S. Department of War and the U.S. Department of Health and Human Services (HHS). Specifically, the goal would be to pilot at-home-potential neuroplastogenic candidates for AUD and other indications. “We believe that continued engagement with federal agencies, alongside rigorous clinical research, is important to advancing new treatment options for patients who currently have limited access to care,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind.

A Year of Federal Engagement

At its core, Clearmind’s case rests on a distinction within the psychedelic category. According to the company, data from its clinical trials at Yale University and Johns Hopkins University suggest that neuroplastogenic compounds can retain the benefits of neuroplasticity enhancement without the hallucinogenic effects of legacy psychedelics. As a result, Clearmind argues, that profile may reduce the need for expensive supervised dosing.

Meanwhile, the submission is the latest in a series of federal touchpoints. In April, Clearmind welcomed an Executive Order supporting accelerated review and patient access pathways for certain psychedelic therapies. Then, in July, it responded to an HHS Request for Information, highlighting its MEAI compound for AUD. On September 14, its Chief of Global Impact, Mary-Elizabeth Gifford, briefed an FDA-convened federal panel that included officials from SAMHSA, the National Institutes of Health and the Veterans Health Administration.

Where CMND-100 Stands

Clearmind’s lead candidate, CMND-100, is in a Phase I/IIa trial for AUD. In August, the company reported that CMND-100 met its primary safety endpoint in Part A, which tested all planned dose levels in healthy participants. An independent data safety monitoring board then unanimously approved advancing to Parts B and C. Next, Part B will enroll two sequential cohorts of six patients with moderate to severe AUD at 80 mg and 160 mg doses, and Clearmind enrolled its first AUD patients at Hadassah Medical Center in Jerusalem in September.

On the balance sheet, Clearmind reported cash of about $12.0 million as of July 31, 2026, up from $3.9 million at October 31, 2025, largely from financing activities. At the same time, net cash used in operating activities was $5.8 million for the nine months. Separately, during the period, the company agreed to acquire a 51% stake in Charging Robotics Ltd., an Israeli wireless charging company, for $2.5 million.

Strategic Investment Summary

• FDA Submission: Clearmind Medicine Inc. (NASDAQ: CMND) submitted recommendations to the FDA on October 7, 2026 on the future therapeutic use of psychedelic drugs.
• At-Home Focus: The company asked the FDA to consider guidance for self-administered and at-home-potential therapies, along with streamlined regulatory pathways.
• Federal Partners: Clearmind proposed pilot collaborations with the VA, the Department of War and HHS for neuroplastogenic AUD candidates.
• Clinical Progress: CMND-100 met its Part A primary safety endpoint and has begun enrolling patients with AUD.
• Policy Track Record: The submission follows Clearmind’s September 14 briefing to an FDA-convened federal panel on patient access.
• Cash Position: Clearmind reported about $12.0 million in cash as of July 31, 2026.

Find out more about the latest corporate developments and financial reports at the Clearmind Medicine investor portal.